Clinical Trial Update: Real World Adherence of PCSK9 Targeted Therapy

View source ↗

Summary

Novartis sponsors a real-world study to evaluate adherence to a PCSK9-targeted therapy in patients with dyslipidemia and hypercholesterolemia; the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypercholesterolemia

Drugs mentioned

• PCSK9-targeted therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dyslipidemia, Hypercholesterolemia | Status: NOT_YET_RECRUITING